Latest Akero Therapeutics News & Updates

See the latest news and media coverage for Akero Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Akero Therapeutics

Clinical-stage biopharmaceutical company

akerotx.com
Headquarters
South San Francisco, United States
Founded year
2017
Company type
Public company
Number of employees
10–70

Latest news about Akero Therapeutics

Company announcements

  • Akero Therapeutics

    Akero Therapeutics attends Baveno VIII Consensus Workshop

    The team joins global experts to establish standards for diagnosing and monitoring portal hypertension in cACLD patients. They emphasize noninvasive methods to advance treatments like EFX.

  • Akero Therapeutics

    Akero Therapeutics reflects on 2025 achievements

    They showed cirrhosis reversal in Phase 2b trial, completed Phase 3 enrollment, and finalized Novo Nordisk acquisition. They anticipate 2026 progress.

  • Akero Therapeutics

    Akero Therapeutics completes acquisition by Novo Nordisk

    This milestone advances efruxifermin for MASH treatment, complementing Novo Nordisk's metabolic disease portfolio.

  • Akero Therapeutics

    Akero Therapeutics shares new efruxifermin data at AASLD

    They present posters and oral sessions on antifibrotic activity from SYMMETRY and HARMONY trials.

Unlock all announcements with a

Media coverage

  • MSN

    Novo Nordisk To Buy Akero Therapeutics for $4.7 Billion

    Under the terms of the deal, Novo Nordisk will initially pay $54 a share in cash, or $4.7 billion, upon closing. Akero shareholders will also...

  • Pharmaceutical Executive

    Novo Nordisk Enters $4.7 Billion Definitive Agreement with Akero Therapeutics | PharmExec

    Novo Nordisk acquires Akero Therapeutics to enhance its portfolio with efruxifermin, a promising treatment for metabolic dysfunction-associated steatohepatitis.

  • Kavout

    What Drove Avoro Capital Advisors' Strategic Exit from Akero Therapeutics

    Avoro Capital Advisors sold its entire stake in Akero Therapeutics for $187.81 million. This strategic exit followed Novo Nordisk's $5.2 billion acquisition of Akero. The...

  • Morningstar

    Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero ...

    Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale...

Unlock all articles with a

Never miss news about Akero Therapeutics

Track Akero Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Akero Therapeutics competitors & trending companies

Browse news for competitors to Akero Therapeutics and other trending companies.